T helper type 17 (Th17) cells have been shown to be pathogenic in autoimmune diseases; however, their role in type 1 diabetes (T1D) remains inconclusive.
AUTOIMMUNITY
20.9K views |
+14 today
 Your new post is loading...
Your new post is loading...
Scoop.it!
Trial finds that immune-based therapy is safe; further trial on effectiveness is planned 
Scoop.it!
Type 1 diabetes mellitus (T1DM), also known as insulin-dependent diabetes, is a chronic disease caused by autoimmune (type 1a) or spontaneous (type 1b) destruction of pancreatic beta cells, resulting in insulin deficiency.
Gilbert C FAURE's insight:
viewed by students
INTRODUCING THE WORLD'S FUTURE THOUGHT LEADERS. Student Pulse is an open-access, multidisciplinary student journal focused on presenting student scholarship in the social sciences, arts, and humanities.
Scoop.it!
Latent Autoimmune Diabetes in Adults (LADA) manifests with symptoms that are similar to other forms of diabetes: excessive thirst and drinking, and excessive urination.
Gilbert C FAURE's insight:
Autoantibody panel This is a panel that can be ordered by your Doctor and consists of Glutamic acid decarboxylase autoantibodies islet cell autoantibodies, insulinoma-associated autoantibodies, and zinc transporter autoantibodies. It is important to note that Glutamic acid decarboxylase antibodies are commonly found in diabetes mellitus type 1. Islet cell antibodies Islet Cell IgG Cytoplasmic Autoantibodies, IFA; Islet Cell Complement Fixing Autoantibodies, Indirect Fluorescent Antibody (IFA); Islet Cell Autoantibodies Evaluation; Islet Cell Complement Fixing Autoantibodies, these are helpful in picking a diagnosis between LADA and type 2 diabetes. Persons with LADA often test positive for ICA, type 2 diabetics only seldom do. Glutamic acid decarboxylase type antibodies ELISA tests include: Anti-GAD, Anti-IA2, Anti-GAD/IA2 Pool, these are helpful in early diagnosis for type 1 diabetes mellitus, and the GAD antibodies tests are used for differential diagnosis between LADA and type 2 diabetes and may also be used for differential diagnosis of gestational diabetes, risk prediction in immediate family members for type 1, as well as a tool to monitor prognosis of the clinical progression of type 1 diabetes. Insulin antibodies These are antibiody tests, they check to see if the body is fighting against itself. They are known as RIA: Anti-GAD, Anti-IA2, Anti-Insulin; Insulin Antibodies all these tests are can be used in early diagnosis for type 1 diabetes mellitus, and they can be used to help tell the difference of LADA and type 2 diabetes, as well as for differential diagnosis of other problems of metabolism such as gestational diabetes, prediction in family members for type 1diabetes and ways to tell if there has been progression of type 1 diabetes. Persons with LADA may test positive for these 3 autoantibodies are not found in persons with type 2 diabetes. How often does this occur? It is estimated that there are up to half of all persons, depending on the type of population, that have diagnosed with type 2 diabetes that may have LADA instead of type 2 diabetes. This number accounts for an estimated about ten percent of the total diabetes population in the U.S. and there may be more than 3.5 million persons have this kind of diabetes called LADA.
Scoop.it!
Professor Rayaz Malik and colleagues outline new guidance on diagnosis and management.
Scoop.it!
New research from the Australian Research Council Centre of Excellence in Advanced Molecular Imaging challenges the assumption that the receptors on the T cells must bind to MHC in a specific orientation in order to trigger a signal to the immune...
Gilbert C FAURE's insight:
diabetes
Scoop.it!
The association between the HLA-G 14-bp insertion/deletion polymorphism and ...
Gilbert C FAURE's insight:
type I diabetes
Scoop.it!
A breakthrough by Australian researchers could change the way T cell receptors (TCRs) are studied, and have implications for type 1 diabetes.
Scoop.it!
NOD-scid.Il2rgnull (NSG) mice are currently being used as recipients to screen for pathogenic autoreactive T cells in type 1 diabetes (T1D) patients.
Scoop.it!
44
Scoop.it!
![[World Report] Profile: Joslin Diabetes Center, Boston, MA, USA | AUTOIMMUNITY | Scoop.it](https://img.scoop.it/mdYZEdNttdZAe_PAFFAuEjl72eJkfbmt4t8yenImKBVvK0kTmF0xjctABnaLJIm9)
The Joslin Diabetes Center has a long history of being on the cutting edge of diabetes care and research. It was founded 117 years ago by Elliott Joslin, a physician dedicated to understanding and treating type 1 diabetes in young people. Via Krishan Maggon
Krishan Maggon 's curator insight,
September 4, 2015 6:45 AM
Lancet Volume 386, No. 9997, p944, 5 September 2015World ReportProfile: Joslin Diabetes Center, Boston, MA, USABrian Owens DOI: http://dx.doi.org/10.1016/S0140-6736(15)00116-6 ;
Scoop.it!
Article Abstract: from Diabetes Journal current issueClick Here To Read Full Article Visit Diabetes Journal current issue for more great articles....
Scoop.it!
PLoS One. 2015 Jul 31;10(7):e0134365. doi: 10.1371/journal.pone.0134365.
|
Scoop.it!
by Lisbeth Hansen, Anja Schmidt-Christensen, Shashank Gupta, Nina Fransén-Pettersson, Tine D.
Scoop.it!
by Douglas C. Chang, Paolo Piaggi, Robert L. Hanson, William C. Knowler, John Bucci, Guene Thio, Maximilian G.
Scoop.it!
The easy way to access online services at the University of Lincoln.
Scoop.it!
A $10 million gift from The Parker Foundation, founded by Silicon Valley entrepreneur and philanthropist Sean Parker, will establish a new research laboratory within the UCSF Diabetes Center devoted to understanding autoimmunity.
Scoop.it!
South San Francisco, CA - The laboratory in the UC San Francisco Diabetes Center will study autoimmune diseases and seek to develop new treatments for diseases. | Patch
Scoop.it!
Non-HLA type 1 diabetes genes modulate disease risk together with HLA-DQ and ...
Scoop.it!
Gilbert C FAURE's insight:
Type 1 Diabetes Genetics Consortium (T1DGC) Autoantibody Workshop
Scoop.it!
Diabetes. 2015 Aug;64(8):3017-27. doi: 10.2337/db14-1730. Epub 2015 Mar 31. Research Support, N.I.H., Extramural
Gilbert C FAURE's insight:
Abstract
Islet autoantibodies detected at disease onset in patients with type 1 diabetes are signs of an autoimmune destruction of the insulin-producing β-cells. To further investigate the genetic determinants of autoantibody positivity, we performed dense immune-focused genotyping on the Immunochip array and tested for association with seven disease-specific autoantibodies in a large cross-sectional cohort of 6,160 type 1 diabetes-affected siblings. The genetic association with positivity for GAD autoantibodies (GADAs), IA2 antigen (IA-2A), zinc transporter 8, thyroid peroxidase, gastric parietal cells (PCAs), tissue transglutaminase, and 21-hydroxylase was tested using a linear mixed-model regression approach to simultaneously control for population structure and family relatedness. Four loci were associated with autoantibody positivity at genome-wide significance. Positivity for GADA was associated with 3q28/LPP, for IA-2A with 1q23/FCRL3 and 11q13/RELA, and for PCAs with 2q24/IFIH1. The 3q28 locus showed association after only 3 years duration and might therefore be a marker of persistent GADA positivity. The 1q23, 11q13, and 2q24 loci were associated with autoantibodies close to diabetes onset and constitute candidates for early screening. Major susceptibility loci for islet autoantibodies are separate from type 1 diabetes risk, which may have consequences for intervention strategies to reduce autoimmunity.
Scoop.it!
Clinical & Translational Immunology focuses on the general functioning of the immune system in its broadest sense, with a particular emphasis on its cell biology.
Scoop.it!
by Xuyan Niu, Cheng Lu, Cheng Xiao, Na Ge, Miao Jiang, Li Li, Yanqin Bian, Gang Xu, Zhaoxiang Bian, Ge Zhang, Aiping Lu Rheumatoid arthritis (RA) and Type 2 diabetes (T2D) are both systemic diseases linked with altered immune response, moderate...
Scoop.it!
Checkpoint inhibitors have an anticancer effect by removing a negative regulatory signal for T-cell activation from the tumor microenvironment (Fig. 1). They include cytotoxic T-cell–associated antigen (CTLA-4), programmed cell death protein-1 (PD-1), and programmed cell death ligand-1 (PDL-1) antibodies and are now being widely used for the treatment of different types of cancer. From the initial phases of checkpoint inhibitor use, there has been concern about the potential for the development of autoimmune disease as a result of T-cell activation. Subsequently, multiple autoimmune diseases were indeed observed as a result of these medications (1). Although both PD-1 and PDL-1 antibodies can precipitate type 1 diabetes in the nonobese diabetic mice model (2), only very recent reports have noted type 1 diabetes after PD-1 antibody use in humans (3,4). Here, we describe two older adults without diabetes receiving agents inhibiting the PD-1 pathway for resistant cancers who developed acute type 1 diabetes. Via Krishan Maggon
Krishan Maggon 's curator insight,
September 2, 2015 11:31 AM
Published online before printJune 26, 2015, doi:10.2337/dc15-0889Diabetes Care September 2015vol. 38 no. 9 e137-e138Anti–PD-1 and Anti–PDL-1 Monoclonal Antibodies Causing Type 1 DiabetesMahnaz Mellati1, Keith D. Eaton2, Barbara M. Brooks-Worrell1,3,William A. Hagopian1,4, Renato Martins2, Jerry P. Palmer1,3 andIrl B. Hirsch1⇑
+Author Affiliations 1Division of Metabolism, Endocrinology and Nutrition, University of Washington, Seattle, WA2Division of Medical Oncology, University of Washington, Seattle, WA3Division of Endocrinology, VA Puget Sound Health Care System, Seattle, WA4Pacific Northwest Diabetes Research Institute, Seattle, WACorresponding author: Irl B. Hirsch, ihirsch@uw.edu.
Krishan Maggon 's curator insight,
September 2, 2015 6:12 PM
Published online before printJune 26, 2015, doi:10.2337/dc15-0889Diabetes Care September 2015vol. 38 no. 9 e137-e138Anti–PD-1 and Anti–PDL-1 Monoclonal Antibodies Causing Type 1 DiabetesMahnaz Mellati1, Keith D. Eaton2, Barbara M. Brooks-Worrell1,3,William A. Hagopian1,4, Renato Martins2, Jerry P. Palmer1,3 andIrl B. Hirsch1⇑ +Author Affiliations 1Division of Metabolism, Endocrinology and Nutrition, University of Washington, Seattle, WA2Division of Medical Oncology, University of Washington, Seattle, WA3Division of Endocrinology, VA Puget Sound Health Care System, Seattle, WA4Pacific Northwest Diabetes Research Institute, Seattle, WACorresponding author: Irl B. Hirsch, ihirsch@uw.edu. 
Remi Creusot's curator insight,
September 4, 2015 8:18 AM
Treatment of cancer requires boosting the immune system, while that of autoimmunity requires restraining it. Thus, cancer drugs that relieve some of the natural breaks of immune response could potentially induce or aggravate autoimmune diseases. Here, we have evidence that biologics blocking the PD1/PDL1 pathway is associated with the development of T1D.
Scoop.it!
Need for #MDx autoimmunity marker for #diabetes onset after anti-PD1 treatment in #oncology #PersonalizedMedicine http://t.co/x2bZhAXz8x
|
